Augmentation of cisplatin cytotoxicity using cytokines on cervical carcinoma cell lines

Cancer Biotherapy and Radiopharmaceuticals

Volumn 11, Issue 6, 1996, Pages 349-354

  Verma, Veena N ^a   Shenoy, Chandrashekhar N ^a   Nadkarni, Jayshree J ^a  

^a TATA MEMORIAL HOSPITAL   (India)

Author keywords

Cervical carcinoma; Cisplatin; Interferon ; Interferon ; TNF

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; BIOLOGICAL RESPONSE MODIFIER; CISPLATIN; CYTOKINE; RECOMBINANT ALPHA INTERFERON; RECOMBINANT GAMMA INTERFERON; RECOMBINANT TUMOR NECROSIS FACTOR ALPHA; THYMIDINE;

ARTICLE; CARCINOMA CELL; CONTROLLED STUDY; CYTOTOXICITY; DRUG SENSITIVITY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; UTERINE CERVIX CARCINOMA;

EID: 0030473573     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.1996.11.349     Document Type: Article

References (19)

1. Dinshaw KA, Shrivastava SK, Muckaden MA, Sharma V, Deore SM, Viswanathan PS. Factors influencing treatment strategies using MDR brachytherapy for cervical cancer: In . Mould RF, Battermann JJ, Martinex AA, Speiser BL (eds). Brachytherapy from Radium to optimization, Nucletron International, Netherlands, 1994;67-78.
2. Angoli R, Sevin B-U, Perras JP, Untch M, Hightower RD, Nguyen HN, Steren A, Villani C, Averette HE. Rationale of combining radiation and IFN for the treatment of the cervical cancer. Oncology 1992;49:445-449.
3. Pierotti MA. Human papilloma virus and cancer. In: Dammacco F. (ed): Advances in Tumor Immunology and Allergic Disorders, Edi-Ermes-milano, 1992:123-138
4. Look KY. Cervix. In: Foley JF, Vose JM, Armitage JO (eds): Current therapy in cancer, WB Saunders Co, 1994;125-128.
5. Raaphorst GP, Doja S, Davis L, Stewart D, Ng CE. A comparison of hyperthermia cisplatin sensitization in human ovarian carcinoma and glioma cell lines sensitive and resistant to cisplatin treatment. Cancer Chemother Pharmacol 1996;37:574-580.
6. Bonavida B, Tsuchitani T, Zighelboim J, Berek JS. Synergy is documented in vitro with low dose recombinant TNF, cisplatin and doxorubicin in ovarian cancer cells Gynecol Oncol 1990,38:333-339
7. Basu S, Sodhi A, Singh SM, Suresh A Upregulation of induction of LAK cell activity by FK565 and cisplatin. Immunol Lett 1991,27:199-204
8. Suresh A, Sodhi A Production of IL-1 and TNF by bone marrow derived macrophages : effect of cisplatin and LPS. Immunol Lett 1991;30 93-100.
9. Wadler S, Schwartz EL. Antineoplastic activity of the combination of Interferon and cytotoxic agents against experimental and human malignancies: a review. Cancer Res 1990;50:3473-3486.
10. Balkwill FR, Ward BG, Moodie E, Fiers W. Therapeutic potential of TNF-a and IFN-g in experimental human ovarian cancer. Cancer Res 1987;47:4755-4764.
11. Borden TC, Sondel PM. Lymphokines and cytokines as cancer treatment: immunotherapy realized. Cancer 1990,65:800-814.
12. Bowman A, Fergussan RJ, Allan SG. Potentiation of Cisplatin by alpha Interferon in advanced non-small cell lung cancer: A phase II study. Am Oncol 1990;1:351-353.
13. Sacchi M, Klapan I, Johnson JT, Whiteside TL. Antiproliferative effects of cytokines on squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 1991,117:321-326.
14. Yip I, Pang X-P, Berg L, Hershman JM. Antitumor actions of IFN-g and IL-1b on human papillary thyroid carcinoma cell lines. J Clin Endocrinol Metab 1995,80:1664-1669.
15. Clark S, McGlukin MA, Hurst T, Ward BG. Effect of IFN-g and TNF-a on sensitivity to Cisplatin in ovarian carcinoma cell lines. Cancer Immunol Immunother 1994,39:100-104
16. Zhang Z-J, Wang J-L, Muhr C, Smits A. Synergistic inhibitory effects of IFN-a and 5-FU on meningioma cells in vitro Cancer Lett 1996,100:99-105.
17. Hand A, Pelin K, Halme M, Ekman A, Mattson M, Valias M, Mattson K. Linnainmaa K, Pursiainen KH. IFN-a and IFN-g combined with chemotherapy: in vitro sensitivity studies in non-small cell lung cancer cell line. Anti-Cancer Drugs 1993;4.365-368.
18. Schiller JH, Bittner G, Storer B, Wilson JKV. Synergistic antitumor effects of TNF and r-IFN on human colon carcinoma cell lines. Cancer Res 1987,47.2809-2813.
19. Dawson DE, Gapany M, Burgess RC, Boesen PV, Headley DB. Tumor necrosis factor and chemotherapeutic agents. Potentiation of cytotoxicity with IFN-g. Arch Otolaryngol Head Neck Surg 1992,118:1168-1171.